Thangaratinam and colleagues aimed to shed light on the potential predictive value of using pulse oximetry to screen for significant cyanotic congenital heart disease (CHD) in newborn infants. One ...
Masimo's NeoPODS study found its SET pulse oximetry technology delivered consistent accuracy in critically ill newborns across all skin tones, addressing longstanding concerns over racial bias in ...
Masimo (Nasdaq:MASI) today announced new study findings supporting the use of its SET pulse oximetry in critically ill neonates.
Masimo’s NeoPODS study in critically ill newborns found its SET pulse oximetry technology delivered consistent accuracy across all skin tones, with less than 1% bias. The findings address longstanding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results